Gynevac

Phase 3Biologic

AAmvac Kft.

Gynevac is one of 20 biologic programs targeting Bacterial Vaginosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bacterial VaginosisActive, not recruiting

Bacterial VaginosisPhase 3

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Bacterial Vaginosis

#DrugCompanyPhaseTrials

Acanya

Pfizer

Approved

3 2

Decadron

AAspen Global Incorporated

Approved

—3

Amoxil

GGlobal Antibiotics Research and Development Partnership

Mycostatin

N-Acetyl Cyteien

1 6

Lactobacillus Acidophilus

UUniversiteit Antwerpen

Approved

1 7

Tindamax

MMission Pharmacal

Phase 3

3 8

Conventional

PPopulation Health Research Institute

Phase 3

1 9

Lactoferrin

UUniversità degli Studi di Ferrara

Phase 3

1 10

Lactoserum

Sanofi

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bacterial Vaginosis1 trial

Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis

Unknown status·AAmvac Kft.·Phase 3·NCT02173184·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gynevac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gynevac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gynevac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amvac Kft. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: AAmvac Kft.

Gynevac

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bacterial Vaginosis1 trial

References

Drug Info

Quick Facts

Related News